Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community How long are Pelage going to milk the phase 2a results of PP405?

      in Chat  21 upvotes 5 months ago
      PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

      community Topical Finasteride with rogain foam as solvent

      in Finasteride/Dutasteride  1 upvotes 4 years ago
      The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.

      community Pyrilutamide update number 2 - 2 week use

      in Update  174 upvotes 3 years ago
      An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

      community Why dont we research more on body hair

      in Chat  32 upvotes 3 months ago
      Body hair is more resilient than scalp hair due to different gene expressions and DHT sensitivity. Treatments like minoxidil and finasteride are used for hair loss, but they have varying effects on body and scalp hair.

      community Anger and frustration as I finally learn my diagnosis.

      in Female  6 upvotes 2 years ago
      A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.